Burkitt's Lymphoma
22
1
2
16
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
11 trials with published results (50%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.6%
3 terminated out of 22 trials
84.2%
-2.3% vs benchmark
9%
2 trials in Phase 3/4
69%
11 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (22)
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Allo HSCT Using RIC for Hematological Diseases
Treatment for Advanced B-Cell Lymphoma
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
Double Cord Versus Haploidentical (BMT CTN 1101)
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
Imexon for Relapsed Follicular and Aggressive Lymphomas
Rituximab Combined With Chemotherapy in Burkitt's Lymphoma